Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ensysce Biosciences, Inc.ENSC · Entity 8108 | Chief Commercial Officer | February 17, 2022 | February 25, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ensysce Biosciences, Inc.
Report date February 17, 2022 · Filed February 25, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2032-02-17 | Direct | 50,000 |
Reported balance
After 2022-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-17 · Grant · Acquired 50,000 · Balance 50,000 F1: On February 17, 2022, Mr. Birkett was granted an option (the "Stock Option") to purchase 50,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 17, 2022, Mr. Birkett was granted an option (the "Stock Option") to purchase 50,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2022 Filed Feb 25, 2022 00:03 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 50,000 | Not disclosed Strike: $1.40 | Not disclosed |
DisclosureSEC source: 0001493152-22-005444 · ownership.xml · derivative · entry 1 Birkett Kevin Geoffrey · CIK 0001867942 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-02-17 F1 · security: On February 17, 2022, Mr. Birkett was granted an option (the "Stock Option") to purchase 50,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. F1 · price: On February 17, 2022, Mr. Birkett was granted an option (the "Stock Option") to purchase 50,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. F1 · derivative.exercise_date: On February 17, 2022, Mr. Birkett was granted an option (the "Stock Option") to purchase 50,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 22:07 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 329,250 | Not disclosed Strike: $2.59 | Not disclosed |
DisclosureSEC source: 0001192482-21-000612 · edgar.xml · derivative · entry 2 Birkett Kevin Geoffrey · CIK 0001867942 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,250 Underlying: Common Stock · 329,250 shares Expires 2029-02-28 F1 · price: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. F1 · derivative.exercise_date: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 22:07 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 19,755 | Not disclosed Strike: $2.59 | Not disclosed |
DisclosureSEC source: 0001192482-21-000612 · edgar.xml · derivative · entry 1 Birkett Kevin Geoffrey · CIK 0001867942 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,755 Underlying: Common Stock · 19,755 shares Expires 2028-10-01 F1 · price: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. F1 · derivative.exercise_date: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.